|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cytostatic potential of new CP inhibitors derived from dipeptidyl nitriles is analyzed <i>in vitro</i> using pancreatic cancer (MIA PaCa-2) cells.
|
30370859 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that AKBA inhibited the proliferation of four different PaCa cell lines (AsPC-1, PANC-28, and MIA PaCa-2 with K-Ras and p53 mutations, and BxPC-3 with wild-type K-Ras and p53 mutation).
|
22066019 |
2011 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the involvement of MK in the development of tumors, we further examined its expression in a variety of human neoplastic cell lines: YMB-1-C (breast cancer), EBC-1 (lung squamous cell carcinoma), RERF-LC-OK (lung adenocarcinoma), SBC-3 (lung small cell carcinoma), HSC-2 (mouth squamous cell carcinoma), NUGC-2 (gastric cancer), COLO201 (colon cancer), HepG2 (hepatoma), MIA PaCa-2 (pancreatic cancer), MCAS (ovarian cancer), HeLa (cervical cancer), BeWo (chorionic carcinoma), ITO-II (testicular tumor), T24 (urinary bladder tumor), and G-401 (Wilms' tumor).
|
8434639 |
1993 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To elucidate whether and how mutant p53 acquires its gain-of-function, mutant p53 is inducibly knocked down in the SW480 colon cancer cell line, which contains mutant p53(R273H/P309S), and the MIA PaCa-2 pancreatic cancer cell line, which contains mutant p53(R248W).
|
18701504 |
2008 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The phosphorylation of GSK-3β (Glycogen synthase kinase-3β) was found to be upregulated in the MIA PaCa-2 and TB32047 cells after <i>GPRC5a</i> knockout.
|
29949874 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HSF1 was downregulated in pancreatic cancer (MIA PaCa-2 and S2-013) and cholangiocarcinoma (KMBC and KMCH) cell lines by HSF1-specific small interfering RNA (siRNA).Nonsilencing siRNA was used as control.
|
21330448 |
2011 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human PaCa cell lines were used to demonstrate that restoration of miRNA-143 (miR-143) regulates COX-2 and inhibits cell proliferation. miR-143 were detected at fold levels of 0.41 ± 0.06 in AsPC-1, 0.20 ± 0.05 in Capan-2 and 0.10 ± 0.02 in MIA PaCa-2. miR-143 was not detected in BxPC-3, HPAF-II and Panc-1 which correlated with elevated mitogen-activated kinase (MAPK) and MAPK kinase (MEK) activation.
|
23973710 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were 1) to investigate the mRNA pattern of CD44 variants in three primary (MIA PaCa 2, PANC-1, PSN-1) and two metastatic (CAPAN-1, SUIT-2) pancreatic cancer (PC) cell lines; 2) to ascertain whether the genetic transfer of CD44s and CD44v10 modifies the adhesion of PC cells to the extracellular matrix (ECM) in vitro and their metastatic behavior in vivo.
|
12841682 |
2003 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
EphA2-knockdown in PANC-1 cells inhibited their ability to transmit exosome-mediated chemoresistance to MIA PaCa-2 and BxPC-3, while treatment of MIA PaCa-2 and BxPC-3 cells with soluble EphA2 did not promote chemoresistance, indicating that membrane carried EphA2 was important for the EphA2 chemoresistance effect.
|
30613276 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the anticancer activity of non-steroidal anti-inflammatory drugs (NSAIDs) in BxPC-3 and MIA PaCa-2 pancreatic cancer cell cultures.
|
29942156 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of berberine on pancreatic cancer stem cells of PANC-1 and MIA PaCa-2.
|
24894821 |
2014 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
To discover novel markers for improving the efficacy of pancreatic cancer (PC) diagnosis, the secretome of two PC cell lines (BxPC-3 and MIA PaCa-2) was profiled.
|
21625447 |
2011 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the anti-tumor effects of MBRI-001 in combination with GEM in BxPC-3 and MIA PaCa-2 human PC cell lines.
|
31802375 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
|
21376256 |
2011 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines.
|
29998364 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA PaCa-2 human pancreatic cancer cells were used.
|
27846148 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurotrophic artemin promotes motility and invasiveness of MIA PaCa-2 pancreatic cancer cells.
|
22901124 |
2012 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells.
|
28058630 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell growth inhibition was measured in MIA PaCa-2 and Panc1 cells for 2 days using CellTiter-Glo kit.
|
30504717 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report here that a tetra-substituted naphthalene-diimide derivative (MM41) has significant in vivo anti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model.
|
26077929 |
2015 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
|
26397991 |
2015 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative proteomic analysis was performed of 102 EV preparations from human pancreatic juices, blood, and pancreatic cancer cell lines Capan-1 and MIA PaCa-2.
|
29550476 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the mechanism of Gem‑R, two Gem‑R PaCa cell lines were established from AsPC‑1 and MIA PaCa‑2 cells.
|
31002348 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, human recombinant nonglycosylated P-irisin (expressed in Escherichia coli prokaryote cell system) or glycosylated E-irisin (expressed in Pichia pastoris eukaryote cell system) were compared to examine the role of recombinant irisin against pancreatic cancer (PC) cells lines, MIA PaCa-2 and Panc03.27.
|
30323244 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analogous experiments using human pancreas cancer MIA PaCa-2 cells provided findings roughly similar to those from the experiments using HCT116 cells except for lack of suppression of metastases by macrophages in NOG hosts.
|
26170385 |
2015 |